Negative regulation of mitosis in fission yeast by the Shk1 interacting protein Skb1 and its human homolog, Skb1Hs

MARY GILBRETH*, PEIRONG YANG*, GEOFFREY BARTHOLOMEUSZ*, RUTH A. PIMENTAL*, SANJAY KANSRA, RAMESH GADIRAJU, AND STEVAN MARCUS†

Department of Molecular Genetics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030

Edited by Michael H. Wigler, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, and approved October 1, 1998 (received for review April 28, 1998)

ABSTRACT We previously provided evidence that the protein encoded by the highly conserved *skb1* **gene is a** putative regulator of Shk1, a p21^{Cdc42/Rac}-activated kinase **(PAK) homolog in the fission yeast** *Schizosaccharomyces pombe. skb1* **null mutants are viable and competent for mating but less elongate than wild-type** *S. pombe* **cells, whereas cells that overexpress** *skb1* **are hyperelongated. These phenotypes suggest a possible role for Skb1 as a mitotic inhibitor. Here we show genetic interactions of both** *skb1* **and** *shk1* **with genes encoding key mitotic regulators in** *S. pombe***. Our results indicate that Skb1 negatively regulates mitosis by a mechanism that is independent of the Cdc2-activating phosphatase Cdc25 but that is at least partially dependent on Shk1 and the Cdc2 inhibitory kinase Wee1. We provide biochemical evidence for association of Skb1 and Shk1 with Cdc2 in** *S. pombe***, suggesting that Skb1 and Shk1 inhibit mitosis through interaction with the Cdc2 complex, rather than by an indirect mechanism. These results provide evidence of a previously undescribed role for PAK-related protein kinases as mitotic inhibitors. We also describe the cloning of a human homolog of** *skb1***,** *SKB1Hs***, and show that it can functionally replace** *skb1* **in** *S. pombe***. Thus, the molecular functions of Skb1-related proteins have likely been substantially conserved through evolution.**

 $p21^{Cdc42/Rac}$ -activated kinases (PAKs) comprise a recently recognized family of protein kinases that are highly conserved in eukaryotes (1). PAKs bind to, and in many cases have been shown to be activated by, the small GTPases Cdc42 and Rac, but do not bind to other small GTPases such as Ras or Rho. Studies in model systems ranging from yeasts to mammalian cells have demonstrated diverse roles for PAKs, including regulation of mitogen-activated protein kinase cascades (2–6), cytoskeletal and morphological regulation (3, 7–9), and induction of apoptosis (10). In the fission yeast *Schizosaccharomyces pombe*, the PAK homolog Shk1 (also called Pak1) is essential for cell viability and is implicated by genetic analyses to play key roles in morphological control and mating response pathways regulated by Ras and Cdc42 GTPases (3, 7). Cdc42 binds to a sequence in the Shk1 regulatory domain that is highly homologous to the $Cdc42/Rac$ binding sites found in the regulatory domains of mammalian PAKs (11, 12). The terminal phenotypes of *cdc42* and *shk1* null mutants are similar, with each resulting in growth arrest as small round cells (3, 7, 13). Whereas genetic experiments suggest that Shk1 is a key effector for Cdc42 in fission yeast (3, 7), overexpression of *shk1* does not suppress the lethality resulting from the *cdc42* null mutation (7) , raising the possibility that Cdc42 may have at least one other essential effector besides Shk1 (7). The molecular targets of Shk1 have not yet been described.

Previously, we reported on the characterization of a novel gene, *skb1*, which was identified by a two-hybrid screen for cDNAs encoding proteins that form complexes with Shk1 (11). The Skb1 protein interacts with a regulatory subdomain of Shk1 positioned between its Cdc42-binding and kinase domains, thus implicating Skb1 as a Shk1 regulator. Unlike *cdc42* and *shk1*, the *skb1* gene is not essential for viability or mating of *S. pombe* cells (11). However, *skb1* null (*skb1*D) mutants are less elongate and exhibit a slightly slower growth rate than wild-type cells. In contrast, cells overexpressing *skb1* are hyperelongated in morphology. Overexpression of *shk1* restores elongate morphology to the $skb1\overline{\Delta}$ mutant, suggesting that Shk1 functions downstream of Skb1 (11). Overexpression of *skb1* partially restores elongate morphology to fission yeast cells carrying a *ras1* null mutation, and this effect is markedly increased by cooverexpressing *skb1* with *shk1* (11). Cumulatively, these data suggest that Skb1 functions to positively modulate Shk1 function *in vivo*.

Interestingly, the cell length defects resulting from loss and gain of *skb1* function bear resemblance to defects resulting from loss and gain of function of certain genes, such as *wee1*, encoding dosage-dependent mitotic inhibitors in *S. pombe* (14–16). As in higher organisms, the initiation of mitosis in fission yeast is dependent on the activity of a cyclin-dependent kinase, Cdc2, and an associated B-type cyclin, Cdc13 (15, 17). Cdc13 is destroyed after completion of mitosis and accumulates during interphase. Cdc2. Cdc13 activity is repressed during interphase as a result of inhibitory phosphorylation of Cdc2 on tyrosine 15 by the related protein kinases Wee1 and Mik1 (18, 19). *S. pombe* cells carrying a *wee1* deletion are viable but exit prematurely from G_2 at a reduced size, whereas overexpression of *wee1* delays G₂ to M progression, causing cells to divide at significantly greater than normal lengths (14–16). The $mik1\Delta$ mutation has little effect on the timing of mitosis, but deletion of both *wee1* and *mik1* is synthetically lethal and results in a condition termed lethal mitosis, in which cells divide at a very small size and exhibit abnormal patterns of chromosome segregation (19). Transition from G_2 to M phase requires that Cdc2 undergo phosphorylation on threonine 167 by a Cdc2-activating kinase, or CAK (20, 21) and dephosphorylation of tyrosine 15, which occurs primarily through the activity of the Cdc2-activating phosphatase Cdc25 (22, 23). Loss of Cdc25 function causes cells to become blocked at G_2 while continuing to accumulate mass and becoming extremely elongated, whereas overexpression of Cdc25, like loss of Wee1, causes cells to exit from G_2 at a reduced size (15, 22). Thus Cdc25, like Wee1, functions in a dosage-dependent fashion.

In the present study, we have investigated the cell-cycle regulatory properties of Skb1 and Shk1. We show genetic interactions of the *skb1* and *shk1* genes with genes encoding

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''*advertisement*'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.

^{© 1998} by The National Academy of Sciences 0027-8424/98/9514781-6\$2.00/0 PNAS is available online at www.pnas.org.

This paper was submitted directly (Track II) to the *Proceedings* office.
Abbreviations: PAKS, p21^{Cdc42/Rac}-activated kinases; GST, glutathione *S*-transferase; t.s., temperature sensitive; JAK, Janus kinase. *These authors contributed equally to this work.

[†]To whom reprint requests should be addressed. e-mail: smarcus@ mdacc.tmc.edu.

key mitotic regulators in *S. pombe* that demonstrate a previously undescribed role for the Skb1 and Shk1 proteins as dosage-dependent mitotic inhibitors. We also show that Cdc2 coprecipitates with Skb1 and Shk1 proteins isolated from *S. pombe* cell lysates, suggesting that Skb1 and Shk1 inhibit mitosis through interaction with the Cdc2 complex rather that by an indirect mechanism. Finally, we provide evidence that Skb1 protein function has been substantially conserved through evolution by showing that a human homolog of *skb1*, *SKB1Hs*, can substitute for *skb1* in *S. pombe*.

MATERIALS AND METHODS

Yeast Strains, Media, and Plasmids. Wild-type *S. pombe* strains used in this study were CHP428 (h ⁺ *ade6-M210 his7*– *366 leu1–32 ura4-D18*) (E. Chang, New York University) and SP870 (*h*⁹⁰ *ade6-M210 leu1–32 ura4-D18*) (D. Beach, Cold Spring Harbor Laboratory). Mutant *S. pombe* strains used were 167 (h⁺ *leu1-32 ura4-D18 cdc25-22*), 137 (h⁻ *leu1-32 ura4-D18 wee1::ura4*), and 41 (h^- *ade6–216 leu1–32 cdc2–3w*) (S. Sazer, Baylor College of Medicine); 606 (h⁻ leu1-32) *ura4-D18 cdc2–1w*) (K. Gould, Vanderbilt University); GL192 (*h*¹ *leu1–32 ura4-D18 cdc2–3w cdc25*::*ura4*) (P. Russell, Scripps Research Institute); SMPY101 and SMMG100 (h⁺ *ade6–210 his7–366 leu1–32 ura4-D18 skb1*::*ura4*), SMMG102 (*h*¹ *ade6–216 his7–366 leu1–32 ura4-D18 cdc25–22 skb1*::*ura4*), SMMG103 (*h*⁹⁰ *ade6-M216 leu1–32 ura4-D18 cdc25–22*), SMMG115 (h⁻ ade6-M210 leu1-32 ura4-D18 wee1::ura4::ADE2), and the *cdc25–22 nmt-shk1* strain SMMG127 (*h*⁹⁰ *ade6-M210 leu1–32 ura4-D18 cdc25–22 shk1*::*ura4*::*ADE2 pREP81Shk1[X-S])*. Cell lengths at division measurements were determined as described (24), by using a phototube micrometer attached to an Olympus B-Max 60 microscope (Olympus, New Hyde Park, NY). At least 20 cells from each culture were measured. Standard yeast genetic methods were performed for construction of *S. pombe* mutants for this study (25). Cultures were grown on either rich medium (YEA) or synthetic minimal medium (EMM) with appropriate auxotrophic supplements (25).

pREP1 (26), pREP81 (27), pREP1Skb1 (for overexpression of *skb1* from the thiamine-repressible *nmt1* promoter) (11), pAAUCM (3), pAAUCMSkb1 (for overexpression of *skb1* from the *adh1* promoter) (11), and pART1CM (28) have been described. pAAUCMShk1 and pART1CMShk1 were constructed by PCR-mediated cloning of a *Bam*HI-*Kpn*I fragment of the full-length *shk1* coding sequence into pAAUCM (*ura4* based) and pART1CM (*LEU2*-based) plasmids, respectively, and allow for expression of *shk1* as a c-myc epitope-tagged protein from the strong *S. pombe adh1* promoter. pREP81Shk1[XS] was constructed by cloning a *Xho*I-*Ssp*I fragment of the *shk1* gene into the plasmid pREP81, a *LEU2*-based plasmid containing a mutationally attenuated version of the *nmt1* promoter (27). The *Xho*I-*Ssp*I fragment of *shk1* is deleted of the 5' end of the *shk1* coding sequence and codes for a Shk1 protein truncated by the deletion of the N-terminal 118 amino acids of the full-length Shk1 protein. This N-terminal truncated Shk1 mutant is nonetheless capable of fully complementing the *shk1* null mutation when expressed from pREP81. pAAUGST was constructed by ligating a 0.7-kb *Sal*Iy*Pst*I-digested, PCR-amplified glutathione *S*-transferase (GST) gene fragment to the corresponding sites of pAAU, a *ura4*-based plasmid similar to pART1 (29), which allows for expression of sequences from the *S. pombe adh1* promoter. pAAUGSTSkb1 was constructed by ligating a *Bam*HI-*Kpn*I $skb1$ fragment from pGADSkb1 Δ N24 into pAAUGST. pAAUGSTShk1 was constructed by PCR-mediated subcloning of the full-length *shk1* coding sequence into pAAUGST.

Preparation of Cell Lysates and Coprecipitation Experiments. *S. pombe* CHP428 transformants expressing GST fusion proteins were grown to about 10⁷ cells per ml in EMM, harvested by centrifugation, resuspended with yeast lysis buffer $[20 \text{ mM Hepes (pH 7.6)/}200 \text{ mM KCl}/2 \text{ mM EGTA}/2$ mM EDTA/10 mM sodium molybdate/50 mM sodium fluoride/2 mM sodium pyrophosphate/1 mM sodium vanadate/ 0.1% Nonidet P-40/10% glycerol/10 μ M E64/100 μ M leupeptin/1 μ M pepstatin A/1 mM phenylmethanesulfonyl fluoride/aprotinin $(2 \mu g/ml)$] and ground with glass beads. Crude lysates were clarified twice by centrifugation at $16,000 \times g$ for 15 min and the supernatant fractions were aliquoted and quick-frozen in liquid nitrogen before being stored at -80° C. The supernatant fractions (1 mg of protein) were incubated with 50 μ l of a 50% slurry of glutathione agarose beads in a volume of 1 ml yeast lysis buffer for 2 hr at 4°C on a rotary rocker. The beads were washed four times with yeast lysis buffer and bound proteins were separated by SDS/PAGE and transferred to nitrocellulose membranes. Western blot analyses were performed by using anti-Cdc2 PSTAIRE (Santa Cruz Biotechnology), anti-GST (Pierce), and anti-Skb1 (to be described elsewhere) polyclonal antibodies.

SKB1Hs cDNA Cloning. The oligonucleotide primers 5'-GAATGGGATCCCCAAGTGACCGTAGTCTCATCA and 59-AGATGAATTCCACCTTCTGTACTACAGGAGCAG were used in PCRs to amplify a fragment of *SKB1Hs* from a HeLa cell cDNA library constructed in the plasmid pEBS7 (kindly provided by R. Legerski, University of Texas M. D. Anderson Cancer Center, Houston, TX). The partial *SKB1Hs* cDNA was used as a probe to screen for the full-length cDNA from the pEBS7 HeLa cell library. Two potential full-length *SKB1Hs* cDNAs were isolated from a screen of about 1.5 million bacterial transformants. A search of the expressed sequence tag databases revealed a clone (GenBank accession no. AA417623) containing an in-frame stop codon 5' of our predicted *SKB1Hs* translational initiation codon. PCR was used to facilitate cloning of the full-length *SKB1Hs* cDNA into the pREP1 and pAAUGST plasmids for expression in *S. pombe*.

RESULTS

Skb1 Is a Dosage-Dependent Mitotic Inhibitor. Cell length measurements showed that *S. pombe skb1* Δ cells divide at about $\langle 90\%$ the length of wild-type cells, whereas cells overexpressing *skb1* divide at $\approx 50\%$ greater than normal length (Table 1). These observations suggested the possibility that Skb1 is a dosage-dependent mitotic inhibitor. To explore further this possibility, we tested for genetic interactions between the *skb1* gene and genes encoding key mitotic regulators in *S. pombe*. The temperature-sensitive (t.s.) *cdc25–22*

Table 1. Cell size at division

	Overexpressed	Length at division,
Strain	gene	μ m
Wild type	none	15.2 ± 0.2
	skb1	23.4 ± 0.6
	shk1	17.4 ± 0.5
$skb1\Delta$	none	13.3 ± 0.4
$cdc2$ -3w $cdc25\Delta$	none	18.3 ± 0.5
	skb1	35.8 ± 1.9
	shk1	27.6 ± 1.0
wee 1 Δ	none	7.7 ± 0.3
	skb1	7.6 ± 0.2
$cdc2-1w$	none	9.0 ± 0.2
	skb1	9.0 ± 0.2
$nmt-shk1$ (33 $^{\circ}$ C)	none	10.9 ± 0.3
$cdc25-22$ (33°C)	none	38.8 ± 1.3
$cdc25-22$ nmt-shk1 (33 $^{\circ}$ C)	none	26.5 ± 0.9

All cultures were grown to log phase at 28°C, unless otherwise indicated. *skb1* was overexpressed from the plasmid pREP1 (*nmt1* promoter). *shk1* was overexpressed from pART1CM (*adh1* promoter). mutation causes *S. pombe* cells to arrest at $G₂$ of the cell cycle when they are shifted to the restrictive temperature of 36°C (14, 30). We predicted that if Skb1 is indeed a mitotic inhibitor, then loss of *skb1* gene function might suppress loss of *cdc25* function. We constructed a $cdc25-22$ $skb1\Delta$ mutant and compared its growth characteristics to that of the *cdc25–22* mutant at the normally nonpermissive temperature of 36°C and at the semipermissive temperature of 33°C. The *cdc25–22* mutant produced no visible colonies on YEA plates incubated at 36°C, whereas the $cdc25-22$ skb1 Δ mutant was capable of growing at 36°C (Fig. 1*A*, *Top*). At 33°C, the *cdc25–22 skb1*D mutant produced substantially larger colonies than the *cdc25–22* mutant (Fig. 1*A*, *Bottom*). These results demonstrate that the t.s. growth defect of the *cdc25–22* mutant can be suppressed by the

FIG. 1. Genetic interactions of *skb1* with genes encoding key mitotic regulators in *S. pombe.* (*A*) The *skb1* null mutation partially suppresses the t.s. growth defect of the *cdc25–22* mutant. *cdc25–22* and *cdc25–22 skb1∆ S. pombe* strains were streaked on YEA plates and incubated at either 36°C (*Top*) or 33°C (*Bottom*). The $cdc25-22$ skb1 Δ mutant strain produced visible colonies at 36°C, whereas the *cdc25–22* strain did not. At 33 \degree C, the *cdc25–22 skb1* \triangle strain grew significantly faster than the *cdc25–22* mutant. (*B*) Overexpression of *skb1* exacerbates the *cdc25–22* t.s. growth defect. The *cdc25–22* mutant was transformed with a plasmid for overexpression of *skb1* (pREP1Skb1) or with a control plasmid (pREP1). Transformants were streaked onto EMM plates and were assayed for growth at 30°C (*Top*) or 33°C (*Bottom*). Overexpression of *skb1* retarded the growth of the *cdc25–22* mutant at 30°C and completely inhibited growth at 33°C. (*C*) *cdc25–22* pREP1- and pREP1Skb1-transformed cells were grown at 26°C in liquid EMM to a density of about $10⁶$ cells per ml then shifted to either 33° C or 36° C and incubated for 5 hr before 4',6-diamidino-2phenylindole (DAPI) staining and microscopic analysis to determine the percentage of binucleated and septated cells in each culture. (*D*) $skb1$ overexpression is inhibitory to the growth of *cdc2–3w cdc25* Δ , but not *cdc2–3w* cells. pREP1- and pREP1Skb1-transformed *cdc2–3w* cells (*Top*) and *cdc2–3w cdc25*∆ cells (*Bottom*) were assayed for growth by being streaked on EMM plates and incubated at 30°C. (*E*) pREP1 and pREP1Skb1-transformed wild-type cells (CHP428) were streaked onto EMM and grown at either 30°C (*Top*) or 36°C (*Bottom*). (*F*) *skb1* overexpression inhibits growth of the $weel \Delta$ mutant at 36°C. pREP1and pREP1Skb1-transformed wee1 Δ cells were streaked onto EMM and grown at either 30°C (*Top*) or 36°C (*Bottom*).

 $skb1\Delta$ mutation. At 36°C, the *cdc25–22 skb1* Δ mutant grew more slowly than a $cdc25-22$ weel Δ mutant (data not shown). We conclude that the $skb1\Delta$ mutation is not as potent a suppressor of the *cdc25–22* t.s. mutation as the *wee* $\hat{I}\Delta$ mutation. This finding is consistent with the observation that $skb1\Delta$ mutants, while shorter than wild-type cells at division, are substantially longer than $\text{wee1}\Delta$ cells (Table 1).

We tested next the effects of *skb1* overexpression in the *cdc25–22* mutant. Overexpression of *skb1* was not inhibitory to the growth of wild-type cells and was only slightly inhibitory to the growth of *cdc25–22* cells at the permissive temperature of 26°C (data not shown). At 30°C, *cdc25–22* cells that overexpressed *skb1* from a high-copy plasmid grew more slowly than cells transformed with a control plasmid (Fig. 1*B*, *Top*). At 33°C, overexpression of *skb1* caused *cdc25–22* cells to become growth arrested, whereas *cdc25–22* cells transformed with a control plasmid were competent for growth (Fig. 1*B*, *Bottom*). These results show that *skb1* overexpression exacerbates the t.s. growth defect of the *cdc25–22* mutant. We observed further microscopically that both *skb1*-overexpressing *cdc25–22* cells incubated at 33°C and *cdc25–22* control cells incubated at 36°C for 5 hr consisted primarily of nonseptated cells containing a single nucleus (Fig. 1*D*). In addition, fluorescence-activated cell-sorting analysis showed virtually identical profiles for *skb1*-overexpressing *cdc25–22* cultures incubated at 33°C and *cdc25–22* control cells incubated at 36°C (data not shown). Taken together, the above-described data suggest that Skb1 functions as a dosage-dependent mitotic inhibitor in *S. pombe*.

To address whether Skb1 inhibits mitosis in a Cdc25 dependent fashion, we examined the effect of *skb1* overexpression in *cdc2–3w* and *cdc2–3w cdc25*D mutants. *cdc2–3w* mutants exhibit reduced responsiveness to the dosage of Cdc25 and retain viability even when the *cdc25* gene is deleted (31). Overexpression of *skb1* had no deleterious effect on the growth of *cdc2–3w* cells (Fig. 1*D*, *Top*). However, *skb1* overexpression was highly inhibitory to the growth of *cdc2–3w cdc25*∆ cells (Fig. 1*D*, *Bottom*) and also caused these cells to divide at about twice the length at which they normally divide (Table 1). These results demonstrate that Skb1 inhibits mitosis by a Cdc25 independent mechanism.

We asked next whether Skb1 inhibits mitosis in a Wee1 dependent fashion. Whereas *skb1* overexpression caused both wild-type and Cdc25-deficient cells to divide at a significantly greater length, it had no effect on the size at which $\text{wee1}\Delta \text{ cells}$ divided (Table 1). In addition, *skb1* overexpression did not inhibit mitosis in the *cdc2–1w* strain (Table 1), a mutant that is largely unresponsive to *wee1* dosage (14–16). These results suggest that Skb1 inhibits mitosis by a Wee1-dependent mechanism. However, further analysis of *skb1* overexpression in *wee1* mutant strains complicated this conclusion. In addition to analyzing the effects of *skb1* overexpression in the *wee1* null mutant, we also overexpressed *skb1* in the *wee1–50* mutant, which carries a t.s. allele of *wee1* (i.e., the *wee1–50* mutant is viable, but exhibits a *wee* phenotype at 36°C). Surprisingly, we found that *skb1* overexpression caused the *wee1–50* mutant to be inhibited severely for growth at 36°C (data not shown). We then assayed $skb1$ -overexpressing $wee1\Delta$ cells for t.s. growth and found that, like the *wee1–50* mutant, *skb1* overexpression caused the $weel\Delta$ mutant to be severely inhibited for growth at 36°C (Fig. 1*F*). Overexpression of *skb1* had no effect on the growth of wild-type cells at 36°C (Fig. 1*E*). Microscopic analysis indicated that $skb1$ -overexpressing $wee1\Delta$ cells were approximately the same length as $weel \Delta$ control cells (data not shown). Thus, *skb1* overexpression does not affect the size at which *wee1* mutant cells divide when incubated at 36°C.

Shk1 Is Required for Skb1-Dependent Mitotic Inhibitory Function. Experiments were performed next to determine whether Skb1 mitotic inhibitory function depends on Shk1. We asked first whether overexpression of *skb1* exacerbates the *cdc25–22* t.s. growth defect in *shk1*-deficient cells. Since *shk1*

is an essential gene, we constructed a *cdc25–22* mutant, SMMG127 (*cdc25–22 nmt1-shk1*), in which *shk1* expression is under the control of a mutationally attenuated allele of the thiamine-repressible *nmt1* promoter (*Methods*). Whereas *skb1* overexpression caused $cdc25-22$ shk1⁺ cells to undergo growth arrest at 33°C (Figs. 1*B* and Fig. 2*A*, *Top*), it did not affect the growth of *cdc25–22 nmt1-shk1* cells at 33°C (Fig. *2A, Bottom*). This result suggests that the mitotic inhibitory function of Skb1 is at least partially dependent on Shk1.

Interestingly, even though *shk1*-deficient (*nmt-shk1*) cells are substantially shorter than $skb1\Delta$ cells (Table 1), the *shk1*-deficient *cdc25–22* strain exhibited the same t.s. growth characteristics as the $cdc25-22$ shk1⁺ strain (data not shown). Thus, unlike the $skb1\Delta$ mutation, $shk1$ deficiency does not suppress the *cdc25-22* t.s. growth defect. However, overexpression of *shk1*, like *skb1*, exacerbated the t.s. growth defect of the *cdc25–22* mutant (Fig. 2*B*) and was highly inhibitory to the growth of $cdc2-3w$ $cdc25\Delta$ mutant (data not shown). Furthermore, cooverexpression of *skb1* and *shk1*, which was only moderately inhibitory to the growth of wild-type *S. pombe* cells (Fig. 2*C*), completely inhibited growth of the *cdc25–22* strain at 30°C (Fig. 2*D*), whereas overexpression of either gene alone, as already noted, resulted in only a retardation of growth of the *cdc25–22* mutant at the same temperature. Thus, cooverexpression of *skb1* and *shk1* is more toxic to the *cdc25–22* mutant than overexpression of either gene alone. *shk1* overexpression, like overexpression of *skb1*, also caused the *wee1* Δ mutant to exhibit a t.s. growth defect (data not shown). Taken together, these various data suggest that Shk1 has a mitotic inhibitory function and that this function is

FIG. 2. Genetic evidence that Shk1 has a mitotic inhibitory function. (*A*) Exacerbation of the *cdc25–22* t.s. growth defect caused by *skb1* overexpression is Shk1-dependent. PAAUCM- and pAAUCM-Skb1-transformed *cdc25–22* (*Top*) and *cdc25–22 nmt-shk1* (*Bottom*) cells were streaked onto \overrightarrow{EMM} containing 15 μ M thiamine and incubated at 33°C for 3 days. (*B*) Overexpression of *shk1* exacerbates the *cdc25–22* t.s. growth defect. The *cdc25–22* mutant was transformed with a plasmid for overexpression of *shk1* (pAAUCMShk1) or with a control plasmid (pAAUCM). Transformants were streaked onto EMM plates and assayed for growth at 30°C (*Top*) and 33°C (*Bottom*). Overexpression of *shk1* retarded the growth of the *cdc25–22* mutant at 30°C and completely inhibited growth at 33°C. (*C*) Cooverexpression of *skb1* and *shk1* is only slightly inhibitory to growth of wild-type (CHP428) *S. pombe* cells. (*D*) Cooverexpression of *skb1* and *shk1* more severely exacerbates the *cdc25-22* t.s. growth defect than overexpression of either gene alone. The *cdc25–22* mutant was transformed with pREP1Skb1 (Skb1) andyor pAAUCMShk1 (Shk1) or with the control plasmids pREP1 and/or pAAUCM. Primary transformants were streaked onto EMM plates and incubated at 30°C. Cooverexpression of *skb1* and *shk1* completely inhibited growth of the *cdc25–22* mutant at 30°C, whereas overexpression of either gene alone only retarded growth.

required for Skb1-dependent mitotic inhibition. However, the failure of *shk1* deficiency to suppress the *cdc25–22* t.s. growth defect, in contrast to loss of *skb1* function, raises the possibility that Skb1 may act on other proteins in addition to Shk1 to inhibit mitosis.

Skb1 and Shk1 Associate with Cdc2 in *S. pombe.* Biochemical experiments were performed to address whether Skb1 and Shk1 are associated with a Cdc2 complex in *S. pombe*. Lysates were prepared from wild-type *S. pombe* cells expressing Skb1 and Shk1 as GST fusion proteins. The supernatant fractions of the cell lysates were incubated with glutathione agarose beads to purify GST fusion proteins and the resulting complexes were resolved by SDS/PAGE and were subjected to immunoblot analysis. As shown in Fig. 3*A*, we detected association of Cdc2 with both GST-Skb1 and GST-Shk1, but not with GST. These results provide evidence that Skb1 and Shk1 associate with a Cdc2 complex in *S. pombe*, suggesting that they inhibit mitosis by a mechanism that involves interaction with a component(s) of that complex, rather than by an indirect mechanism. Using this same strategy, we were able also to coprecipitate Skb1 with a GST fusion of an N-terminally truncated Shk1 protein (Shk1 Δ N) lacking the first 116 amino acids of the full length Shk1 sequence, but only from cells in which Skb1 was overexpressed (Fig. 3*B*). This result provides biochemical confirmation of the Skb1–Shk1 two-hybrid interaction, which we described in a previous report (11). We were unable to assay for coprecipitation of Skb1 with GST-full length Shk1 because cooverexpression of the two proteins was toxic to *S. pombe* cells (data not shown).

Functional Homology of *S. pombe* **and Human Skb1 Proteins.** In our original report on the cloning and characterization of *skb1*, we described a partial sequence for a human homolog of *skb1*, *SKB1Hs*, which we derived from overlapping EST sequences identified from a BLAST search of the nucleic acid databases (11). We have since cloned and sequenced a probable full-length *SKB1Hs* cDNA (GenBank accession no. AF015913) (*Materials and Methods*). The predicted Skb1Hs

FIG. 3. Skb1 and Shk1 associate with Cdc2 and with each other in fission yeast. (*A*) *S. pombe* strain CHP428 was transformed with plasmids for expression of GST (pAAUGST), GST-Skb1 (pAAUG-STSkb1), or GST-Shk1 (pAAUGSTShk1) fusion proteins. Transformants were grown to about 10⁷ cells per ml in EMM, then lysed and GST complexes precipitated as described in *Methods*. Complexes were resolved by SDS/PAGE and transferred to nitrocellulose. Immunoblotting was performed by using anti-Cdc2 PSTAIRE antibody (*Top*). Membranes were then stripped and reprobed with anti-GST antibody (*Bottom*). Cdc2 protein was associated with GST-Skb1 and GST-Shk1, but not with GST. (*B*) Shk1 and Skb1 proteins associate in *S. pombe* cells. Lysates were prepared from CHP428 cells overexpressing *skb1* and either GST or GST-Shk1 Δ N, as described for *A*. GST and GST-Shk1 Δ N complexes were resolved by SDS/PAGE and subjected to immunoblot analysis by using anti-Skb1 antibody (*Top*). Blots were subsequently stripped and probed with anti-GST antibody (*Bottom)*. Skb1 protein was associated with GST-Shk1 Δ N, but not with GST.

9.4 kb-
6.5- 4.3

 $2.3 -$

protein is 39% identical to *S. pombe* Skb1 (henceforth Skb1Sp) and 34% identical to a predicted Skb1-related protein, Skb1Ce, encoded by the uncharacterized *Caenorhabditis elegans* ORF CE34E10.5 (Fig. 4). Human genomic DNA digested with either *Bam*HI or *Eco*RI was subjected to Southern blot analysis by using the *SKB1Hs* cDNA as a probe (Fig. 4*B*). Single hybridizing bands were produced from each digest. No additional bands were detected under low-stringency hybridization conditions (data not shown), suggesting that there are no other genes closely related to *SKB1Hs* at the nucleic acid sequence level.

A plasmid was constructed for expressing *SKB1Hs* in *S. pombe* from the *nmt1* promoter. Expression of *SKB1Hs* not only caused wild-type *S. pombe* cells to divide at a significantly greater length, but also restored greater than wild-type length to *skb1*D cells (Fig. 5*A*). Furthermore, expression of *SKB1Hs* exacerbated the t.s. growth defect of both *cdc25–22* (not shown) and $cdc25-22$ skb1 Δ (Fig. 5B) mutants and was highly inhibitory to the growth of $cdc2-3w$ $cdc25\Delta$ cells (Fig. 5*C*). In addition, Cdc2 coprecipitated with Skb1Hs GST fusion protein

FIG. 5. Skb1Hs functions as a mitotic inhibitor in *S. pombe.* (*A*) Cell division size data for wild-type and $skb1\Delta$ cells transformed with pREP1Skb1Hs, for expression of *SKB1Hs* from the *S. pombe nmt1* promoter, or the control plasmid pREP1. *SKB1Hs* expression causes wild-type and $skb1\Delta$ cells to divide at a substantially greater length. (*B*) *SKB1Hs* expression exacerbates the t.s. growth defect of a *cdc25–22 skb1*D mutant (*Bottom*), but does not inhibit the growth of wild-type *S. pombe* cells (*Top*). (*C*) *SKB1Hs* expression is inhibitory to the growth of *cdc2–3w cdc25*D mutant (*Bottom*) but not the *cdc2–3w* mutant (*Top*). (*D*) Cdc2 associates with GST-Skb1Hs protein in fission yeast. Cells expressing either GST or GST-Skb1Hs were grown to log phase, lysed, and GST complexes isolated and subjected to immunoblot analysis with anti-Cdc2 and anti-GST antibody, as described in Fig. 3.

in *S. pombe* cells (Fig. 5*D*). These results demonstrate that the Skb1Sp and SKB1Hs proteins are conserved substantially in function.

DISCUSSION

In conclusion, we have provided evidence that the protein encoded by the highly conserved *skb1* gene negatively regulates mitosis in *S. pombe* by a mechanism that is at least partially dependent on the PAK homolog Shk1 and the Cdc2 inhibitory kinase Wee1. Our results provide evidence of a previously undescribed role for PAK-related protein kinases as mitotic inhibitors. We have provided biochemical evidence that Skb1Sp and Shk1 associate with Cdc2 in *S. pombe*, suggesting that the mitotic inhibitory activities of Skb1Sp and Shk1 occur through interaction with the Cdc2 complex, rather than by an indirect mechanism. The simplest model accounting for our results would place Skb1Sp and Shk1 function upstream of Wee1. However, our results do not rule out the possibility that Skb1Sp and Shk1 act in a codependent parallel pathway that converges on Cdc2 with the Wee1 pathway. Indeed, our finding that overexpression of either *skb1Sp* or *shk1* causes *wee1* mutants to exhibit t.s. growth defects may be an indication that Skb1Sp and Shk1 do, in fact, function in a pathway parallel to that of Wee1. We have found that purified recombinant Skb1Sp and Shk1 proteins do not inhibit Cdc2·Cdc13 activity *in vitro* (R.P. and S.M., unpublished results), suggesting that Skb1 and Shk1 do not likely act directly on Cdc2.

Skb1Sp is a member of a novel, but highly conserved, family of proteins that are apparently ubiquitous in eukaryotic organisms. We have shown here that a human homolog of Skb1Sp, Skb1Hs, can functionally substitute for Skb1Sp in *S. pombe*. This result suggests that Skb1 protein function has been remarkably conserved through evolution. It will be interesting to determine whether Skb1-related proteins, together with PAK-related kinases, function as mitotic regulators in higher organisms. Interestingly, Pollack and colleagues have cloned *SKB1Hs* from a two-hybrid screen for Janus kinase (JAK)2 interacting proteins (B. Pollack and S. Pestka, personal communication). This interaction suggests the possibility that Skb1Hs could link JAK2 to a PAK signaling pathway in mammalian cells, a hypothesis consistent with the observation that certain ligands that activate JAKs also activate PAKs (32). Moreover, since JAKs are activated both by ligands that have proliferative effects, such as erythropoietin, and by ligands with antiproliferative effects, such as interferon (33), the possibility exists that Skb1 proteins could link JAK-mediated signaling pathways to cell-cycle control complexes.

An *skb1*-related gene, *HSL7*, has also been cloned from *S. cerevisiae* as a result of a genetic screen for mutations that are lethal in combination with a deletion of the histone H3 amino terminus (34). Interestingly, *S. cerevisiae* cells carrying an *hsl7* null mutation exhibit a G_2 delay. This phenotype is in striking contrast to that of *S. pombe skb1Sp* null mutants, which exit prematurely from G2. Based on these results, it would appear that Skb1Sp and Hsl7 have opposite functions, with Skb1Sp being a mitotic inhibitor in *S. pombe* and Hsl7 possibly functioning as a mitotic inducer in *S. cerevisiae*. The mitotic delay caused by the *hsl7* mutation is suppressed by deletion of the *swe1* gene, which encodes the single *S. cerevisiae* homolog of Wee1 (34). Thus, Hsl7 interacts genetically with Swe1, although in a fashion opposite to the Skb1–Wee1 interaction in *S. pombe*. Unlike *skb1Sp*, no gain-of-function phenotype(s) have yet been described for *HSL7,* and such phenotypes would be highly useful for further clarifying the role of Hsl7 during mitosis in *S. cerevisiae*. We have found that, unlike human Skb1Hs, Hsl7 cannot substitute for Skb1Sp in *S. pombe* (P.Y. and S.M., unpublished results), suggesting that Skb1Sp and Skb1Hs are more closely related in function than either is to $Hsl7$

Genetic data suggest that Shk1 performs at least two distinct functions in *S. pombe*. One function is required for normal mating response, which is not essential for cell viability or normal cell shape, and which involves interaction between Shk1 and a Ras-dependent mitogen-activated protein kinase pathway (3, 7, 35). The second Shk1-dependent function is essential for cell viability and, possibly, normal morphology (3, 7). At this time, it is unclear whether the cell-cycle regulatory functions of Shk1 are distinct from its function(s) as a morphological regulator. It also remains to be established whether the essential function(s) of Shk1 are related to its role(s) as a mitotic and morphological regulator. Further elucidation of Shk1-mediated cellular functions will be greatly facilitated by the identification of potential downstream targets for Shk1, and we are presently conducting screens to identify such targets.

Note Added in Proof. Krapivinsky *et al*. (36) have identified Skb1Hs as a protein that binds to a potential chloride channel protein called pICln.

We thank Anjana Kundu for technical assistance; Kathy Gould, Vicki Huff, Randy Legerski, Nick Rhind, and Shelley Sazer for strains and materials; and Jenny Henkel, Nick Rhind, and Anthony Polverino for comments on the manuscript. M.G. was supported by a National Institutes of Health predoctoral training grant. This work was supported by National Institutes of Health Grant R01GM53239 (to S.M.).

- 1. Sells, M. A. & Chernoff, J. (1997) *Trends Cell Biol.* **7,** 162–167.
- 2. Polverino, A., Frost, J., Yang, P., Hutchison, M., Neiman, A. M., Cobb, M. H. & Marcus, S. (1995) *J. Biol. Chem.* **270,** 26067– 26070.
- 3. Marcus, S., Polverino, A., Chang, E., Robbins, D., Cobb, M. H. & Wigler, M. H. (1995) *Proc. Natl. Acad. Sci. USA* **92,** 6180–6184.
- 4. Leberer, E., Dignard, D., Harcus, D., Thomas, D. Y. & Whiteway, M. (1992) *EMBO J.* **11,** 4815–4824.
- 5. Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J. & Bokoch, G. M. (1995) *J. Biol. Chem.* **270,** 23934–23936.
- 6. Frost, J. A., Xu, S., Hutchison, M. R., Marcus, S. & Cobb, M. H. (1996) *Mol. Cell. Biol.* **16,** 3707–3713.
- 7. Ottilie, S., Miller, P. J., Johnson, D. I., Creasy, C. L., Sells, M. A., Bagrodia, S., Forsburg, S. L. & Chernoff, J. (1995) *EMBO J.* **14,** 5908–5919.
- 8. Manser, E., Huang, H. Y., Loo, T. H., Chen, X. Q., Dong, J. M., Leung, T. & Lim, L. (1997) *Mol. Cell. Biol.* **17,** 1129–1143.
- 9. Sells, M. A., Knaus, U. G., Bagrodia, S., Ambrose, D. M., Bokoch, G. M. & Chernoff, J. (1997) *Curr. Biol.* **7,** 202–210.
- 10. Rudel, T. & Bokoch, G. M. (1997) *Science* **276,** 1571–1574.
- 11. Gilbreth, M., Yang, P., Wang, D., Frost, J., Polverino, A., Cobb, M. H. & Marcus, S. (1996) *Proc. Natl. Acad. Sci. USA* **93,** 13802–13807.
- 12. Burbelo, P. D., Drechsel, D. & Hall, A. (1995) *J. Biol. Chem.* **270,** 29071–29074.
- 13. Miller, P. J. & Johnson, D. I. (1994) *Mol. Cell. Biol.* **14,** 1075– 1083.
- 14. Russell, P. & Nurse, P. (1987) *Cell* **49,** 559–567.
- 15. Forsburg, S. L. & Nurse, P. (1991) *Annu. Rev. Cell Biol.* **7,** 227–256.
- 16. Wu, L. & Russell, P. (1997) *EMBO J.* **16,** 1342–1350.
- 17. Okayama, H., Nagata, A., Jinno, S., Murakami, H., Tanaka, K. & Nakashima, N. (1996) *Adv. Cancer Res.* **69,** 17–62.
- 18. Parker, L. L., Atherton-Fessler, S. & Piwnica-Worms, H. (1992) *Proc. Natl. Acad. Sci. USA* **89,** 2917–2921.
- 19. Lundgren, K., Walworth, N., Booher, R., Dembski, M., Kirschner, M. & Beach, D. (1991) *Cell* **64,** 1111–1122.
- 20. Gould, K. L., Moreno, S., Owen, D. J., Sazer, S. & Nurse, P. (1991) *EMBO J.* **10,** 3297–3309.
- 21. Buck, V., Russell, P. & Millar, J. B. (1995) *EMBO J.* **14,** 6173–6183.
- 22. Russell, P. & Nurse, P. (1986) *Cell* **45,** 145–153.
- 23. Millar, J. B., McGowan, C. H., Lenaers, G., Jones, R. & Russell, P. (1991) *EMBO J.* **10,** 4301–4309.
- 24. Thuriaux, P., Nurse, P. & Carter, B. (1978) *Mol. Gen. Genet.* **161,** 215–220.
- 25. Alfa, C., Fantes, P., Hyams, J., McLeod, M. & Warbrick, E. (1993) *Experiments with Fission Yeast: A Laboratory Course Manual* (Cold Spring Harbor Lab. Press, Plainview, NY*)*.
- 26. Maundrell, K. (1990) *J. Biol. Chem.* **265,** 10857–10864.
- 27. Basi, G., Schmid, E. & Maundrell, K. (1993) *Gene* **123,** 131–136. 28. Chang, E. C., Barr, M., Wang, Y., Jung, V., Xu, H. P. & Wigler,
- M. H. (1994) *Cell* **79,** 131–141.
- 29. McLeod, M., Stein, M. & Beach, D. (1987) *EMBO J.* **6,** 729–736. 30. Fantes, P. (1979) *Nature (London)* **279,** 428–430.
- 31. Millar, J. B., Lenaers, G. & Russell, P. (1992) *EMBO J.* **11,**
- 4933–4941. 32. Teo, M., Manser, E. & Lim, L. (1995) *J. Biol. Chem.* **270,**
- 26690–26697.
- 33. Ihle, J. N. (1996) *Philos. Trans. R. Soc. Lond. B* **351,** 159–166.
- 34. Ma, X. J., Lu, Q. & Grunstein, M. (1996) *Genes Dev.* **10,** 1327–1340.
- 35. Yang, P., Kansra, S., Pimental, R. A., Gilbreth, M. & Marcus, S. (1998) *J. Biol. Chem.* **273,** 18481–18489.
- 36. Krapivinsky, G., Pu, W., Wickman, K., Krapivinsky, L. & Clapham, D. E. (1998) *J. Biol. Chem.* **273,** 10811–10814.